POLG-related disorders and their neurological manifestations

Shamima Rahman, William C Copeland, Shamima Rahman, William C Copeland

Abstract

The POLG gene encodes the mitochondrial DNA polymerase that is responsible for replication of the mitochondrial genome. Mutations in POLG can cause early childhood mitochondrial DNA (mtDNA) depletion syndromes or later-onset syndromes arising from mtDNA deletions. POLG mutations are the most common cause of inherited mitochondrial disorders, with as many as 2% of the population carrying these mutations. POLG-related disorders comprise a continuum of overlapping phenotypes with onset from infancy to late adulthood. The six leading disorders caused by POLG mutations are Alpers-Huttenlocher syndrome, which is one of the most severe phenotypes; childhood myocerebrohepatopathy spectrum, which presents within the first 3 years of life; myoclonic epilepsy myopathy sensory ataxia; ataxia neuropathy spectrum; autosomal recessive progressive external ophthalmoplegia; and autosomal dominant progressive external ophthalmoplegia. This Review describes the clinical features, pathophysiology, natural history and treatment of POLG-related disorders, focusing particularly on the neurological manifestations of these conditions.

Conflict of interest statement

Competing interests

The authors declare no competing interests.

Figures

Figure 1 |
Figure 1 |
The clinical spectrum of POLG-related disease. Clinical spectrum of POLG-related disease according to age of onset, and the defects (mitochondrial DNA (mtDNA) depletion or deletions) associated with the diseases. AHS, Alpers–Huttenlocher syndrome; ANS, ataxia neuropathy spectrum; MCHS, myocerebrohepatopathy spectrum; MELAS, mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes; MEMSA, myoclonic epilepsy myopathy sensory ataxia; MNGIE, mitochondrial neurogastrointestinal encephalopathy; PEO, progressive external ophthalmoplegia; SANDO, sensory ataxia neuropathy dysarthria and ophthalmoplegia; SCAE, spinocerebellar ataxia with epilepsy.
Figure 2 |
Figure 2 |
POLG mutations. Mutation map depicting disease-associated amino acid substitutions on the primary structure of POLG. In each panel, the top line depicts the 23 exons of the cDNA and the lower line represents the linear polypeptide with the functional domains (exonuclease and polymerase) indicated. The polymerase active site is subdivided into thumb, palm and fingers subdomains. A full list of disease-related substitutions can be found in the Human DNA Polymerase Gamma Mutation Database. Asterisks indicate mutations that have also been identified as frequent single nucleotide polymorphisms.a | Mutations associated with Alpers–Huttenlocher syndrome and other infantile hepatocerebral syndromes that cause mitochondrial DNA depletion. b | Mutations associated with progressive external ophthalmoplegia (PEO). c | Other mutations linked to POLG-related disease. ANS, ataxia neuropathy spectrum; MIRAS, mitochondrial recessive ataxia syndrome; NRTI, nucleoside reverse transcriptase inhibitor; SANDO, sensory ataxia neuropathy dysarthria and ophthalmoplegia; SCAE, spinocerebellar ataxia with epilepsy.
Figure 2 |
Figure 2 |
POLG mutations. Mutation map depicting disease-associated amino acid substitutions on the primary structure of POLG. In each panel, the top line depicts the 23 exons of the cDNA and the lower line represents the linear polypeptide with the functional domains (exonuclease and polymerase) indicated. The polymerase active site is subdivided into thumb, palm and fingers subdomains. A full list of disease-related substitutions can be found in the Human DNA Polymerase Gamma Mutation Database. Asterisks indicate mutations that have also been identified as frequent single nucleotide polymorphisms.a | Mutations associated with Alpers–Huttenlocher syndrome and other infantile hepatocerebral syndromes that cause mitochondrial DNA depletion. b | Mutations associated with progressive external ophthalmoplegia (PEO). c | Other mutations linked to POLG-related disease. ANS, ataxia neuropathy spectrum; MIRAS, mitochondrial recessive ataxia syndrome; NRTI, nucleoside reverse transcriptase inhibitor; SANDO, sensory ataxia neuropathy dysarthria and ophthalmoplegia; SCAE, spinocerebellar ataxia with epilepsy.
Figure 2 |
Figure 2 |
POLG mutations. Mutation map depicting disease-associated amino acid substitutions on the primary structure of POLG. In each panel, the top line depicts the 23 exons of the cDNA and the lower line represents the linear polypeptide with the functional domains (exonuclease and polymerase) indicated. The polymerase active site is subdivided into thumb, palm and fingers subdomains. A full list of disease-related substitutions can be found in the Human DNA Polymerase Gamma Mutation Database. Asterisks indicate mutations that have also been identified as frequent single nucleotide polymorphisms.a | Mutations associated with Alpers–Huttenlocher syndrome and other infantile hepatocerebral syndromes that cause mitochondrial DNA depletion. b | Mutations associated with progressive external ophthalmoplegia (PEO). c | Other mutations linked to POLG-related disease. ANS, ataxia neuropathy spectrum; MIRAS, mitochondrial recessive ataxia syndrome; NRTI, nucleoside reverse transcriptase inhibitor; SANDO, sensory ataxia neuropathy dysarthria and ophthalmoplegia; SCAE, spinocerebellar ataxia with epilepsy.

References

    1. Kukat C et al. Super-resolution microscopy reveals that mammalian mitochondrial nucleoids have a uniform size and frequently contain a single copy of mtDNA. Proc Natl Acad Sci USA 108 13534–13539, (2011).
    1. Korhonen JA, Pham XH, Pellegrini M & Falkenberg M Reconstitution of a minimal mtDNA replisome in vitro. EMBO J 23, 2423–2429 (2004).
    1. Copeland WC & Longley MJ Mitochondrial genome maintenance in health and disease. DNA Repair (Amst) 19, 190–198 (2014).
    1. Bebenek K & Kunkel TA Functions of DNA polymerases. Adv Protein Chem 69, 137–165 (2004).
    1. Ropp PA & Copeland WC Cloning and characterization of the human mitochondrial DNA polymerase, DNA polymerase gamma. Genomics 36, 449–458 (1996).
    1. Sweasy JB, Lauper JM & Eckert KA DNA polymerases and human diseases. Radiat Res 166, 693–714 (2006).
    1. Graziewicz MA, Longley MJ & Copeland WC DNA polymerase gamma in mitochondrial DNA replication and repair. Chem Rev 106, 383–405 (2006).
    1. Kaguni LS DNA polymerase gamma, the mitochondrial replicase. Annu Rev Biochem 73, 293–320 (2004).
    1. Lim SE, Longley MJ & Copeland WC The mitochondrial p55 accessory subunit of human DNA polymerase gamma enhances DNA binding, promotes processive DNA synthesis, and confers N-ethylmaleimide resistance. J Biol Chem 274, 38197–38203 (1999).
    1. Young MJ, Humble MM, DeBalsi KL, Sun KY & Copeland WC POLG2 disease variants: analyses reveal a dominant negative heterodimer, altered mitochondrial localization and impaired respiratory capacity. Hum Mol Genet 24, 5184–5197 (2015).
    1. Johnson AA, Tsai Y, Graves SW & Johnson KA Human mitochondrial DNA polymerase holoenzyme: reconstitution and characterization. Biochemistry 39, 1702–1708 (2000).
    1. Van Goethem G, Dermaut B, Lofgren A, Martin JJ & Van Broeckhoven C Mutation of POLG is associated with progressive external ophthalmoplegia characterized by mtDNA deletions. Nat Genet 28, 211–212 (2001).
    1. Van Goethem G et al. POLG mutations in neurodegenerative disorders with ataxia but no muscle involvement. Neurology 63, 1251–1257 (2004).
    1. Van Goethem G et al. Recessive POLG mutations presenting with sensory and ataxic neuropathy in compound heterozygote patients with progressive external ophthalmoplegia. Neuromuscul Disord 13, 133–142 (2003).
    1. Hakonen AH et al. Mitochondrial DNA polymerase W748S mutation: a common cause of autosomal recessive ataxia with ancient European origin. Am J Hum Genet 77, 430–441 (2005).
    1. Naviaux RK & Nguyen KV POLG mutations associated with Alpers’ syndrome and mitochondrial DNA depletion. Ann Neurol 55, 706–712 (2004).
    1. Naviaux RK & Nguyen KV POLG mutations associated with Alpers syndrome and mitochondrial DNA depletion. Ann Neurol 58, 491 (2005).
    1. Winterthun S et al. Autosomal recessive mitochondrial ataxic syndrome due to mitochondrial polymerase gamma mutations. Neurology 64, 1204–1208 (2005).
    1. Woodbridge P, Liang C, Davis RL, Vandebona H & Sue CM POLG mutations in Australian patients with mitochondrial disease. Intern Med J 43, 150–156 (2013).
    1. Rahman S Mitochondrial disease and epilepsy. Dev Med Child Neurol 54, 397–406 (2012).
    1. Bugiardini E et al. Clinicopathologic and molecular spectrum of RNASEH1-related mitochondrial disease. Neurol Genet 3, e149 (2017).
    1. Schicks J, Synofzik M, Schulte C & Schols L POLG, but not PEO1, is a frequent cause of cerebellar ataxia in Central Europe. Mov Disord 25, 2678–2682 (2010).
    1. Gorman GS et al. Prevalence of nuclear and mitochondrial DNA mutations related to adult mitochondrial disease. Ann Neurol 77, 753–759 (2015).
    1. Saneto RP & Naviaux RK Polymerase gamma disease through the ages. Dev Disabil Res Rev 16, 163–174 (2010).
    1. Wong LJ et al. Molecular and clinical genetics of mitochondrial diseases due to POLG mutations. Hum Mutat 29, E150–E172 (2008).
    1. Hikmat O et al. The clinical spectrum and natural history of early-onset diseases due to DNA polymerase gamma mutations. Genet Med 19, 1217–1225 (2017).
    1. Harding BN Progressive neuronal degeneration of childhood with liver disease (Alpers-Huttenlocher syndrome): a personal review. J Child Neurol 5, 273–287 (1990).
    1. Wolf NI et al. Status epilepticus in children with Alpers’ disease caused by POLG1 mutations: EEG and MRI features. Epilepsia 50, 1596–1607 (2009).
    1. Uusimaa J et al. Homozygous W748S mutation in the POLG1 gene in patients with juvenile-onset Alpers syndrome and status epilepticus. Epilepsia 49, 1038–1045 (2008).
    1. Visser NA et al. Juvenile-onset Alpers syndrome: interpreting MRI findings. Neurology 74, 1231–1233 (2010).
    1. Wiltshire E et al. Juvenile Alpers disease. Arch Neurol 65, 121–124 (2008).
    1. Isohanni P et al. POLG1 manifestations in childhood. Neurology 76, 811–815 (2011).
    1. Harris MO, Walsh LE, Hattab EM & Golomb MR Is it ADEM, POLG, or both? Arch Neurol 67, 493–496 (2010).
    1. Naviaux RK et al. Mitochondrial DNA polymerase gamma deficiency and mtDNA depletion in a child with Alpers’ syndrome. Ann Neurol 45, 54–58 (1999).
    1. Whittaker RG et al. Epilepsy in adults with mitochondrial disease: a cohort study. Ann Neurol 78, 949–957 (2015).
    1. Anagnostou ME, Ng YS, Taylor RW & McFarland R Epilepsy due to mutations in the mitochondrial polymerase gamma (POLG) gene: a clinical and molecular genetic review. Epilepsia 57, 1531–1545 (2016).
    1. Van Goethem G et al. Patient homozygous for a recessive POLG mutation presents with features of MERRF. Neurology 61, 1811–1813 (2003).
    1. Deschauer M et al. MELAS associated with mutations in the POLG1 gene. Neurology 68, 1741–1742 (2007).
    1. Orsucci D et al. Revisiting mitochondrial ocular myopathies: a study from the Italian Network. J Neurol 264, 1777–1784 (2017).
    1. Luoma P et al. Parkinsonism, premature menopause, and mitochondrial DNA polymerase gamma mutations: clinical and molecular genetic study. Lancet 364, 875–882 (2004).
    1. Pagnamenta AT et al. Dominant inheritance of premature ovarian failure associated with mutant mitochondrial DNA polymerase gamma. Hum Reprod 21, 2467–2473 (2006).
    1. Hanisch F et al. SANDO syndrome in a cohort of 107 patients with CPEO and mitochondrial DNA deletions. J Neurol Neurosurg Psychiatry 86, 630–634 (2015).
    1. Mancuso M et al. “Mitochondrial neuropathies”: a survey from the large cohort of the Italian Network. Neuromuscul Disord 26, 272–276 (2016).
    1. Menezes MP et al. Neurophysiological profile of peripheral neuropathy associated with childhood mitochondrial disease. Mitochondrion 30, 162–167 (2016).
    1. Hikmat O et al. The presence of anaemia negatively influences survival in patients with POLG disease. J Inherit Metab Dis 40, 861–866 (2017).
    1. Prasun P & Koeberl DD Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE)-like phenotype in a patient with a novel heterozygous POLG mutation. J Neurol 261, 1818–1819 (2014).
    1. Tang S, Dimberg EL, Milone M & Wong LJ Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE)-like phenotype: an expanded clinical spectrum of POLG1 mutations. J Neurol 259, 862–868 (2012).
    1. Van Goethem G et al. Novel POLG mutations in progressive external ophthalmoplegia mimicking mitochondrial neurogastrointestinal encephalomyopathy. Eur J Hum Genet 11, 547–549 (2003).
    1. Martikainen MH, Paivarinta M, Jaaskelainen S & Majamaa K Successful treatment of POLG-related mitochondrial epilepsy with antiepileptic drugs and low glycaemic index diet. Epileptic Disord 14, 438–441 (2012).
    1. Martikainen MH et al. Clinical, genetic, and radiological features of extrapyramidal movement disorders in mitochondrial disease. JAMA Neurol 73, 668–674 (2016).
    1. Davidzon G et al. Early-onset familial parkinsonism due to POLG mutations. Ann Neurol 59, 859–862 (2006).
    1. Johansen KK, Bindoff LA, Rydland J & Aasly JO Palatal tremor and facial dyskinesia in a patient with POLG1 mutation. Mov Disord 23, 1624–1626 (2008).
    1. Nicastro N, Ranza E, Antonarakis SE & Horvath J Pure progressive ataxia and palatal tremor (PAPT) associated with a new polymerase gamma (POLG) mutation. Cerebellum 15, 829–831 (2016).
    1. Synofzik M et al. Complex hyperkinetic movement disorders associated with POLG mutations. Mov Disord 25, 2472–2475 (2010).
    1. Hinnell C et al. Dystonia in mitochondrial spinocerebellar ataxia and epilepsy syndrome associated with novel recessive POLG mutations. Mov Disord 27, 162–163 (2012).
    1. Pitceathly RD et al. Distal myopathy with cachexia: an unrecognised phenotype caused by dominantly-inherited mitochondrial polymerase gamma mutations. J Neurol Neurosurg Psychiatry 84, 107–110 (2013).
    1. Duncan AJ, Knight JA, Costello H, Conway GS & Rahman S POLG mutations and age at menopause. Hum Reprod 27, 2243–2244 (2012).
    1. Giordano C et al. Fatal congenital myopathy and gastrointestinal pseudo-obstruction due to POLG1 mutations. Neurology 72, 1103–1105 (2009).
    1. Lewis W, Day BJ & Copeland WC Mitochondrial toxicity of NRTI antiviral drugs: an integrated cellular perspective. Nat Rev Drug Discov 2, 812–822 (2003).
    1. Young MJ Off-target effects of drugs that disrupt human mitochondrial dna maintenance. Front Mol Biosci 4, 74 (2017).
    1. Dalakas MC et al. Mitochondrial myopathy caused by long-term zidovudine therapy. N Engl J Med 322, 1098–1105 (1990).
    1. Arnaudo E et al. Depletion of muscle mitochondrial DNA in AIDS patients with zidovudine-induced myopathy. Lancet 337, 508–510 (1991).
    1. Dagan T, Sable C, Bray J & Gerschenson M Mitochondrial dysfunction and antiretroviral nucleoside analog toxicities: what is the evidence? Mitochondrion 1, 397–412 (2002).
    1. Lewis W, Copeland WC & Day B Mitochondrial DNA depletion, oxidative stress, and mutation: mechanisms of nucleoside reverse transcriptase inhibitor toxicity. Lab Invest 81, 777–790 (2001).
    1. Tzoulis C et al. The spectrum of clinical disease caused by the A467T and W748S POLG mutations: a study of 26 cases. Brain 129, 1685–1692 (2006).
    1. Nadanaciva S & Will Y New insights in drug-induced mitochondrial toxicity. Curr Pharm Des 17, 2100–2112 (2011).
    1. Neeve VC et al. What is influencing the phenotype of the common homozygous polymerase-gamma mutation p.Ala467Thr? Brain 135, 3614–3626 (2012).
    1. Rajakulendran S et al. A clinical, neuropathological and genetic study of homozygous A467T POLG-related mitochondrial disease. PLoS ONE 11, e0145500 (2016).
    1. Lee YS, Kennedy WD & Yin YW Structural insight into processive human mitochondrial DNA synthesis and disease-related polymerase mutations. Cell 139, 312–324 (2009).
    1. Szymanski MR et al. Structural basis for processivity and antiviral drug toxicity in human mitochondrial DNA replicase. EMBO J 34, 1959–1970 (2015).
    1. Euro L, Farnum GA, Palin E, Suomalainen A & Kaguni LS Clustering of Alpers disease mutations and catalytic defects in biochemical variants reveal new features of molecular mechanism of the human mitochondrial replicase, Pol gamma. Nucleic Acids Res 39, 9072–9084 (2011).
    1. Nurminen A, Farnum GA & Kaguni LS Pathogenicity in POLG syndromes: DNA polymerase gamma pathogenicity prediction server and database. BBA Clin 7, 147–156 (2017).
    1. Scuderi C et al. The in cis T251I and P587L POLG1 base changes: description of a new family and literature review. Neuromuscul Disord 25, 333–339 (2015).
    1. Meyer JN et al. Mitochondria as a target of environmental toxicants. Toxicol Sci 134, 1–17 (2013).
    1. Cohen BH, Chinnery PF & Copeland WC POLG-Related Disorders. In GeneReviews (eds Adam MP et al.) (University of Washington, Seattle, 1997–2010, last updated 2010).
    1. Gattermann N, Berneburg M, Heinisch J, Aul C & Schneider W Detection of the ageing-associated 5-Kb common deletion of mitochondrial DNA in blood and bone marrow of hematologically normal adults. Absence of the deletion in clonal bone marrow disorders. Leukemia 9, 1704–1710 (1995).
    1. Michikawa Y, Mazzucchelli F, Bresolin N, Scarlato G & Attardi G Aging-dependent large accumulation of point mutations in the human mtDNA control region for replication. Science 286, 774–779 (1999).
    1. Longley MJ, Nguyen D, Kunkel TA & Copeland WC The fidelity of human DNA polymerase gamma with and without exonucleolytic proofreading and the p55 accessory subunit. J Biol Chem 276, 38555–38562 (2001).
    1. Longley MJ, Ropp PA, Lim SE & Copeland WC Characterization of the native and recombinant catalytic subunit of human DNA polymerase gamma: identification of residues critical for exonuclease activity and dideoxynucleotide sensitivity. Biochemistry 37, 10529–10539 (1998).
    1. Zheng W, Khrapko K, Coller HA, Thilly WG & Copeland WC Origins of human mitochondrial point mutations as DNA polymerase gamma-mediated errors. Mutat Res 599, 11–20 (2006).
    1. Kennedy SR, Salk JJ, Schmitt MW & Loeb LA Ultra-sensitive sequencing reveals an age-related increase in somatic mitochondrial mutations that are inconsistent with oxidative damage. PLoS Genet 9, e1003794 (2013).
    1. Cortopassi GA, Shibata D, Soong NW & Arnheim N A pattern of accumulation of a somatic deletion of mitochondrial DNA in aging human tissues. Proc Natl Acad Sci USA 89, 7370–7374 (1992).
    1. Cortopassi GA & Arnheim N Detection of a specific mitochondrial DNA deletion in tissues of older humans. Nucleic Acids Res 18, 6927–6933 (1990).
    1. Larsson NG & Clayton DA Molecular genetic aspects of human mitochondrial disorders. Annu Rev Genet 29, 151–178 (1995).
    1. Trifunovic A et al. Premature ageing in mice expressing defective mitochondrial DNA polymerase. Nature 429, 417–423 (2004).
    1. Kujoth GC et al. Mitochondrial DNA mutations, oxidative stress, and apoptosis in mammalian aging. Science 309, 481–484 (2005).
    1. Vermulst M et al. Mitochondrial point mutations do not limit the natural lifespan of mice. Nat Genet 39, 540–543 (2007).
    1. Vermulst M et al. DNA deletions and clonal mutations drive premature aging in mitochondrial mutator mice. Nat Genet 40, 392–394 (2008).
    1. Engelsen BA et al. POLG1 mutations cause a syndromic epilepsy with occipital lobe predilection. Brain 131, 818–828 (2008).
    1. Tzoulis C, Schwarzlmuller T, Biermann M, Haugarvoll K & Bindoff LA Mitochondrial DNA homeostasis is essential for nigrostriatal integrity. Mitochondrion 28, 33–37 (2016).
    1. Tzoulis C et al. Severe nigrostriatal degeneration without clinical parkinsonism in patients with polymerase gamma mutations. Brain 136, 2393–2404 (2013).
    1. Suomalainen A et al. FGF-21 as a biomarker for muscle-manifesting mitochondrial respiratory chain deficiencies: a diagnostic study. Lancet Neurol 10, 806–818 (2011).
    1. Yatsuga S et al. Growth differentiation factor 15 as a useful biomarker for mitochondrial disorders. Ann Neurol 78, 814–823 (2015).
    1. Hasselmann O et al. Cerebral folate deficiency and CNS inflammatory markers in Alpers disease. Mol Genet Metab 99, 58–61 (2010).
    1. Echaniz-Laguna A et al. POLG1 variations presenting as multiple sclerosis. Arch Neurol 67, 1140–1143 (2010).
    1. McKiernan P et al. Incidence of primary mitochondrial disease in children younger than 2 years presenting with acute liver failure. J Pediatr Gastroenterol Nutr 63, 592–597 (2016).
    1. Palin EJ, Hakonen AH, Korpela M, Paetau A & Suomalainen A Mitochondrial recessive ataxia syndrome mimicking dominant spinocerebellar ataxia. J Neurol Sci 315, 160–163 (2012).
    1. Kirschenbaum D, Hedberg-Oldfors C, Oldfors A, Scherer E & Budka H Distinctive cerebral neuropathology in an adult case of sensory ataxic neuropathy with dysarthria and ophthalmoplegia (SANDO) syndrome. Neuropathol Appl Neurobiol 44, 639–642 (2018).
    1. Hakonen AH et al. Abundance of the POLG disease mutations in Europe, Australia, New Zealand, and the United States explained by single ancient European founders. Eur J Hum Genet 15, 779–783 (2007).
    1. Kremer LS et al. Genetic diagnosis of Mendelian disorders via RNA sequencing. Nat Commun 8, 15824 (2017).
    1. Nikkanen J et al. A complex genomic locus drives mtDNA replicase POLG expression to its disease-related nervous system regions. EMBO Mol Med 10, 13–21 (2018).
    1. Uusimaa J et al. Prospective study of POLG mutations presenting in children with intractable epilepsy: prevalence and clinical features. Epilepsia 54, 1002–1011 (2013).
    1. Ferrari G et al. Infantile hepatocerebral syndromes associated with mutations in the mitochondrial DNA polymerase-gammaA. Brain 128, 723–731 (2005).
    1. de Vries MC et al. Multiple oxidative phosphorylation deficiencies in severe childhood multisystem disorders due to polymerase gamma (POLG1) mutations. Eur J Pediatr 166, 229–234 (2007).
    1. Horvath R et al. Phenotypic spectrum associated with mutations of the mitochondrial polymerase gamma gene. Brain 129, 1674–1684 (2006).
    1. Nguyen KV, Sharief FS, Chan SS, Copeland WC & Naviaux RK Molecular diagnosis of Alpers syndrome. J Hepatol 45, 108–116 (2006).
    1. Luoma PT et al. Functional defects due to spacer-region mutations of human mitochondrial DNA polymerase in a family with an ataxia-myopathy syndrome. Hum Mol Genet 14, 1907–1920 (2005).
    1. Chan SS, Longley MJ & Copeland WC The common A467T mutation in the human mitochondrial DNA polymerase (POLG) compromises catalytic efficiency and interaction with the accessory subunit. J Biol Chem 280, 31341–31346 (2005).
    1. Chan SS, Longley MJ & Copeland WC Modulation of the W748S mutation in DNA polymerase gamma by the E1143G polymorphismin mitochondrial disorders. Hum Mol Genet 15, 3473–3483 (2006).
    1. Chan SSL, Longley MJ & Copeland WC Modulation of the W748S mutation in DNA polymerase gamma by the E1143G polymorphism in mitochondrial disorders. Hum Mol Genet 15, 3473–3483 (2006).
    1. Kasiviswanathan R, Longley MJ, Chan SS & Copeland WC Disease mutations in the human mitochondrial DNA polymerase thumb subdomain impart severe defects in mitochondrial DNA replication. J Biol Chem 284, 19501–19510 (2009).
    1. DeBalsi KL, Longley MJ, Hoff KE & Copeland WC Synergistic effects of the in cis T251I and P587L mitochondrial dna polymerase gamma disease mutations. J Biol Chem 292, 4198–4209 (2017).
    1. Graziewicz MA, Longley MJ, Bienstock RJ, Zeviani M & Copeland WC Structure-function defects of human mitochondrial DNA polymerase in autosomal dominant progressive external ophthalmoplegia. Nat Struct Mol Biol 11, 770–776 (2004).
    1. Ponamarev MV, Longley MJ, Nguyen D, Kunkel TA & Copeland WC Active site mutation in DNA polymerase gamma associated with progressive external ophthalmoplegia causes error-prone DNA synthesis. J Biol Chem 277, 15225–15228 (2002).
    1. Viscomi C & Zeviani M MtDNA-maintenance defects: syndromes and genes. J Inherit Metab Dis 40, 587–599 (2017).
    1. van Baalen A, Vezzani A, Hausler M & Kluger G Febrile infection-related epilepsy syndrome: clinical review and hypotheses of epileptogenesis. Neuropediatrics 48, 5–18 (2017).
    1. Rahman S Gastrointestinal and hepatic manifestations of mitochondrial disorders. J Inherit Metab Dis 36, 659–673 (2013).
    1. Staufner C et al. Recurrent acute liver failure due to NBAS deficiency: phenotypic spectrum, disease mechanisms, and therapeutic concepts. J Inherit Metab Dis 39, 3–16 (2016).
    1. Bindoff LA & Engelsen BA Mitochondrial diseases and epilepsy. Epilepsia 53 (Suppl. 4), 92–97 (2012).
    1. McFarland R et al. Reversible valproate hepatotoxicity due to mutations in mitochondrial DNA polymerase gamma (POLG1). Arch. Dis. Child 93, 151–153 (2008).
    1. Saneto RP et al. POLG DNA testing as an emerging standard of care before instituting valproic acid therapy for pediatric seizure disorders. Seizure 19, 140–146 (2010).
    1. Pruss H & Holtkamp M Ketamine successfully terminates malignant status epilepticus. Epilepsy Res 82, 219–222 (2008).
    1. Visser NA et al. Magnesium treatment for patients with refractory status epilepticus due to POLG1-mutations. J Neurol 258, 218–222 (2011).
    1. Dhamija R, Moseley BD & Wirrell EC Clinical reasoning: a 10-month-old boy with myoclonic status epilepticus. Neurology 76, e22–e25 (2011).
    1. Lupashko S, Malik S, Donahue D, Hernandez A & Perry MS Palliative functional hemispherectomy for treatment of refractory status epilepticus associated with Alpers’ disease. Childs Nerv Syst 27, 1321–1323 (2011).
    1. Pfeffer G, Majamaa K, Turnbull DM, Thorburn D & Chinnery PF Treatment for mitochondrial disorders. Cochrane Database Syst Rev 4, CD004426 (2012).
    1. Bell EA et al. Treatment of valproic acid-associated hepatic failure with orthotopic liver transplantation. Ann Pharmacother 26, 18–21 (1992).
    1. Hynynen J et al. Acute liver failure after valproate exposure in patients with POLG1 mutations and the prognosis after liver transplantation. Liver Transpl 20, 1402–1412 (2014).
    1. Thomson MA, Lynch S, Strong R, Shepherd RW & Marsh W Orthotopic liver transplantation with poor neurologic outcome in valproate-associated liver failure: a need for critical risk-benefit appraisal in the use of valproate. Transplant Proc 32, 200–203 (2000).
    1. McKiernan P Acute liver failure after valproate exposure: Liver transplantation may be indicated beyond childhood. Liver Transpl 20, 1287–1289 (2014).
    1. Mindikoglu AL et al. Valproic acid-associated acute liver failure in children: case report and analysis of liver transplantation outcomes in the United States. J Pediatr 158, 802–807 (2011).
    1. Santra S, Gilkerson RW, Davidson M & Schon EA Ketogenic treatment reduces deleted mitochondrial DNAs in cultured human cells. Ann Neurol 56, 662–669 (2004).
    1. Ahola-Erkkila S et al. Ketogenic diet slows down mitochondrial myopathy progression in mice. Hum Mol Genet 19, 1974–1984 (2010).
    1. Spiegler J, Stefanova I, Hellenbroich Y & Sperner J Bowel obstruction in patients with Alpers-Huttenlocher syndrome. Neuropediatrics 42, 194–196 (2011).
    1. Khan A et al. Alpers syndrome: the natural history of a case highlighting neuroimaging, neuropathology, and fat metabolism. J Child Neurol 27, 636–640 (2012).
    1. Hughes SD et al. The ketogenic diet component decanoic acid increases mitochondrial citrate synthase and complex I activity in neuronal cells. J Neurochem 129, 426–433 (2014).
    1. Chang P et al. Seizure control by decanoic acid through direct AMPA receptor inhibition. Brain 139, 431–443 (2016).
    1. Kanabus M et al. The pleiotropic effects of decanoic acid treatment on mitochondrial function in fibroblasts from patients with complex I deficient Leigh syndrome. J Inherit Metab Dis 39, 415–426 (2016).
    1. Pitayu L et al. Combined use of Saccharomyces cerevisiae, Caenorhabditis elegans and patient fibroblasts leads to the identification of clofilium tosylate as a potential therapeutic chemical against POLG-related diseases. Hum Mol Genet 25, 715–727 (2016).
    1. Taanman JW, Muddle JR & Muntau AC Mitochondrial DNA depletion can be prevented by dGMP and dAMP supplementation in a resting culture of deoxyguanosine kinase-deficient fibroblasts. Hum Mol Genet 12, 1839–1845 (2003).
    1. Lopez-Gomez C et al. Deoxycytidine and deoxythymidine treatment for thymidine kinase 2 deficiency. Ann Neurol 81, 641–652 (2017).
    1. Bulst S et al. In vitro supplementation with dAMP/dGMP leads to partial restoration of mtDNA levels in mitochondrial depletion syndromes. Hum Mol Genet 18, 1590–1599 (2009).
    1. Di Meo I et al. Effective AAV-mediated gene therapy in a mouse model of ethylmalonic encephalopathy. EMBO Mol Med 4, 1008–1014 (2012).
    1. Torres-Torronteras J et al. Hematopoietic gene therapy restores thymidine phosphorylase activity in a cell culture and a murine model of MNGIE. Gene Ther 18, 795–806 (2011).
    1. Ahmed N, Ronchi D & Comi GP Genes and pathways involved in adult onset disorders featuring muscle mitochondrial DNA instability. Int J Mol Sci 16, 18054–18076 (2015).
    1. Longley MJ et al. Mutant POLG2 disrupts DNA polymerase gamma subunits and causes progressive external ophthalmoplegia. Am J Hum Genet 78, 1026–1034 (2006).
    1. Spelbrink JN et al. Human mitochondrial DNA deletions associated with mutations in the gene encoding Twinkle, a phage T7 gene 4-like protein localized in mitochondria. Nat Genet 28, 223–231 (2001).
    1. Reyes A et al. RNASEH1 Mutations impair mtDNA replication and cause adult-onset mitochondrial encephalomyopathy. Am J Hum Genet 97, 186–193 (2015).
    1. Stiles AR et al. Mutations in TFAM, encoding mitochondrial transcription factor A, cause neonatal liver failure associated with mtDNA depletion. Mol Genet Metab 119, 91–99 (2016).
    1. Nicholls TJ et al. Topoisomerase 3alpha is required for decatenation and segregation of human mtDNA. Mol Cell 69, 9–23.e26 (2018).
    1. Ronchi D et al. Mutations in DNA2 link progressive myopathy to mitochondrial DNA instability. Am J Hum Genet 92, 293–300 (2013).
    1. Kornblum C et al. Loss-of-function mutations in MGME1 impair mtDNA replication and cause multisystemic mitochondrial disease. Nat Genet 45, 214–219 (2013).
    1. Kaukonen J et al. Role of adenine nucleotide translocator 1 in mtDNA maintenance. Science 289, 782–785 (2000).
    1. Nishino I, Spinazzola A & Hirano M Thymidine phosphorylase gene mutations in MNGIE, a human mitochondrial disorder. Science 283, 689–692 (1999).
    1. Saada A et al. Mutant mitochondrial thymidine kinase in mitochondrial DNA depletion myopathy. Nat Genet 29, 342–344 (2001).
    1. Mandel H et al. The deoxyguanosine kinase gene is mutated in individuals with depleted hepatocerebral mitochondrial DNA. Nat Genet 29, 337–341 (2001).
    1. Bourdon A et al. Mutation of RRM2B, encoding p53-controlled ribonucleotide reductase (p53R2), causes severe mitochondrial DNA depletion. Nat Genet 39, 776–780 (2007).
    1. Elpeleg O et al. Deficiency of the ADP-forming succinyl-CoA synthase activity is associated with encephalomyopathy and mitochondrial DNA depletion. Am J Hum Genet 76, 1081–1086 (2005).
    1. Ostergaard E et al. Deficiency of the alpha subunit of succinate-coenzyme A ligase causes fatal infantile lactic acidosis with mitochondrial DNA depletion. Am J Hum Genet 81, 383–387 (2007).
    1. Spinazzola A et al. MPV17 encodes an inner mitochondrial membrane protein and is mutated in infantile hepatic mitochondrial DNA depletion. Nat Genet 38, 570–575 (2006).
    1. Besse A et al. The GABA transaminase, ABAT, is essential for mitochondrial nucleoside metabolism. Cell Metab 21, 417–427 (2015).
    1. Stewart JD et al. OPA1 in multiple mitochondrial DNA deletion disorders. Neurology 71, 1829–1831 (2008).
    1. Rouzier C et al. The MFN2 gene is responsible for mitochondrial DNA instability and optic atrophy ‘plus’ phenotype. Brain 135, 23–34 (2012).
    1. Bonnen PE et al. Mutations in FBXL4 cause mitochondrial encephalopathy and a disorder of mitochondrial DNA maintenance. Am J Hum Genet 93, 471–481 (2013).
    1. Di Bella D et al. Mutations in the mitochondrial protease gene AFG3L2 cause dominant hereditary ataxia SCA28. Nat Genet 42, 313–321 (2010).
    1. Elleuch N et al. Mutation analysis of the paraplegin gene (SPG7) in patients with hereditary spastic paraplegia. Neurology 66, 654–659 (2006).
    1. Di Fonzo A et al. The mitochondrial disulfide relay system protein GFER is mutated in autosomal-recessive myopathy with cataract and combined respiratory-chain deficiency. Am J Hum Genet 84, 594–604 (2009).
    1. Craig K et al. The A467T and W748S POLG substitutions are a rare cause of adult-onset ataxia in Europe. Brain 130, E69 (2007).
    1. Bicknese AR, May W, Hickey WF & Dodson WE Early childhood hepatocerebral degeneration misdiagnosed as valproate hepatotoxicity. Ann Neurol 32, 767–775 (1992).
    1. Delarue A et al. Inappropriate liver transplantation in a child with Alpers-Huttenlocher syndrome misdiagnosed as valproate-induced acute liver failure. Pediatr Transplant 4, 67–71 (2000).
    1. Kayihan N, Nennesmo I, Ericzon BG & Nemeth A Fatal deterioration of neurological disease after orthotopic liver transplantation for valproic acid-induced liver damage. Pediatr Transplant 4, 211–214 (2000).
    1. Parikh S et al. Solid organ transplantation in primary mitochondrial disease: proceed with caution. Mol Genet Metab 118, 178–184 (2016).

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren